Icon (NASDAQ:ICLR) Given New $140.00 Price Target at Citigroup

Icon (NASDAQ:ICLR) had its target price lifted by equities research analysts at Citigroup from $120.00 to $140.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Citigroup’s price target points to a potential upside of 1.59% from the stock’s current price.

A number of other research analysts also recently commented on the company. Barclays increased their target price on Icon from $120.00 to $150.00 and gave the stock an “equal weight” rating in a report on Friday. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the stock a “neutral” rating in a report on Tuesday, February 17th. Bank of America restated an “underperform” rating and set a $105.00 price objective on shares of Icon in a research report on Wednesday. Royal Bank Of Canada increased their target price on Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Friday. Finally, Piper Sandler lowered Icon to a “neutral” rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $153.00.

Icon Stock Performance

NASDAQ:ICLR traded up $1.02 during trading hours on Friday, reaching $137.82. 774,945 shares of the stock were exchanged, compared to its average volume of 1,592,380. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a 50 day simple moving average of $112.28 and a 200-day simple moving average of $141.50. Icon has a 52 week low of $66.57 and a 52 week high of $211.00. The stock has a market capitalization of $11.13 billion, a P/E ratio of 22.38, a P/E/G ratio of 3.09 and a beta of 1.23.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, May 27th. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $2.95 by ($0.43). Icon had a return on equity of 10.58% and a net margin of 7.40%.The firm had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the prior year, the business earned $3.43 EPS. The company’s quarterly revenue was up 2.5% on a year-over-year basis. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, sell-side analysts forecast that Icon will post 11.53 earnings per share for the current fiscal year.

Institutional Trading of Icon

Several hedge funds have recently added to or reduced their stakes in ICLR. Toth Financial Advisory Corp bought a new stake in Icon during the 4th quarter valued at $27,000. EFG International AG bought a new stake in Icon during the 4th quarter valued at $27,000. Ameriflex Group Inc. bought a new stake in Icon during the 3rd quarter valued at $33,000. Abound Financial LLC bought a new stake in Icon during the 4th quarter valued at $54,000. Finally, Johnson Financial Group Inc. bought a new stake in Icon during the 3rd quarter valued at $71,000. Institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.